Abstracts

Measures of ART Adherence Associated with Virological Failure in Rakai Uganda

Background: Adherence is a major predictor of antiretroviral therapy failure; however, viral load monitoring, which is the gold standard for monitoring the efficacy of HIV treatment and measuring validity of adherence reports, is often not feasible in resource limited settings. Simple adherence measures are available in the ART program in Rakai, Uganda, including measures based…

Measures of Retention in HIV Care Differ in Their Associations With Clinical HIV Outcomes

Background: Retaining HIV-infected persons in care is important to receiving antiretroviral therapy (ART) and suppressing viral load. Multiple measures of retention are currently in use with no clear gold standard. Identifying which measures are most closely associated with favorable clinical outcomes may inform how we monitor retention in HIV care. Methodology: We conducted a serial…

Immune Virologic and Adherence Measures as Time-Dependent Predictors of Loss to Follow-Up

Background: For programs supporting large numbers of patients on ART, loss to follow-up (LTFU) and inadequate adherence pose major obstacles in achieving successful outcomes. In preliminary analyses examining patterns and predictors of attrition, we found that baseline CD4+ cell counts, baseline viral loads and early adherence patterns were associated with overall LTFU. In this evaluation,…

A Low CD4/CD8 Ratio During Effective ART Predicts Immunosenescence and Morbidity/Mortality

Background: A low CD4/CD8 ratio in elderly HIV-uninfected adults is associated with increased morbidity and mortality. A subset of HIV-infected adults receiving ART fails to normalize this ratio, even after a normal peripheral CD4 count is obtained. The immunologic and clinical characteristics of this clinical phenotype remain undefined. Methodology: We evaluated the associations of the…

CD4:CD8 Ratio Remains Significantly Depressed Despite Viral Suppression with Effective ART

Background: Inverted CD4:CD8 ratio is known to be indicative of advanced, untreated HIV infection. In the HIV-uninfected population, a low CD4:CD8 ratio has also been associated with near-term mortality in the elderly. This study aimed to characterize the CD4:CD8 ratio in untreated and treated HIV-infection, and to determine the relative dynamics of changes in each…

CMV and HIV: a Double Hit on the CD4/CD8 Ratio

Background: Advanced age is associated with a number of immunologic abnormalities, including a low CD4/CD8 ratio and increased frequency of terminally-differentiated CD8+ T cells (“immunosenescence”). CMV infection significantly contributes to this immunosenescent phenotype. Although HIV infection is associated with high levels of CMV-related inflammatory responses and many of the classic markers of immunosenescence, the relative…

CMV Reactivation and Immune Aging in HIV-infected Individuals Virologically Suppressed on ART

Background: Immune abnormalities including T cell and macrophage/monocyte activation and immune senescence have been associated with ageassociated co-morbidities in HIV. We hypothesize that reactivation of chronic herpes viruses (specifically CMV) may drive the persistent immune changes in HIV infection- despite good control with ART. We aim to define the occurrence of CMV reactivation and its…

Cervical Abnormalities in HIV-Infected South African Women with High Screening and Referral Rates

Background: Access to antiretroviral therapy (ART) has improved in South Africa (SA), enabling HIV-infected women to live longer and healthier lives. However, they remain at increased risk of mortality from cervical cancer, the leading cause of cancer-related deaths. This study aims to advance our understanding of the prevalence of screening, cervical dysplasia, and histologic diagnoses…

Baseline Data of a Phase 3 Trial of the Quadrivalent HPV Vaccine in HIV+ Males and Females: ACTG 5298

Background: Human papillomavirus (HPV) is the main cause of anogenital and oropharyngeal squamous cell cancer. The prophylactic quadrivalent HPV vaccine (qHPV 6, 11, 16, 18) is indicated for males and females aged 9-26 years. A5298 is an ongoing randomized placebo controlled phase 3 study of the qHPV vaccine to prevent anal HPV infection. Methodology: Entry…